Vasopressor Properties of No Synthase Inhibitor T1059. Part II. Hemodynamic Effects on Hypovolemic Disorders

The NO synthase inhibitor T1059 (1-cyclohexanoyl-2-ethylisothiourea hydrobromide) in experiments modeling acute hemorrhagic shock with a single parenteral injection at nontoxic doses (i.p., 10 mg/kg; i.m., 30 mg/kg) showed pronounced hypertensive activity that was much longer than that of phenylephrine and reduced short-term mortality of experimental animals. The results indicated that further pharmacological development of T1059 was promising to design an original domestic drug with antishock activity that is acceptable at the prehospital treatment stage.